Mounjaro Side Effects: Common, Serious and Long Term

Mounjaro (tirzepatide) is a once-weekly injectable medicine approved for type 2 diabetes in adults. It is also approved for chronic weight management in adults with obesity in the United Kingdom and several other countries. It works well for many people, but understanding the possible side effects before starting treatment is important. Most side effects are gut-related, tend to appear during the first few weeks of treatment or after dose increases, and often improve as the body adjusts. A smaller number can be more serious and may need prompt medical attention.

This article explains the side effects you may experience with Mounjaro, which symptoms should not be ignored, and what is currently known about its long-term use and safety.

Mounjaro contains tirzepatide, the first medicine in a class called dual GIP and GLP-1 receptor (glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor) agonists. While semaglutide-based medicines like Ozempic activate one hormonal pathway, tirzepatide activates two. It binds to both GLP-1 receptors, which reduce appetite and slow digestion, and GIP receptors, which influence how the body stores fat and responds to energy. This dual action is why Mounjaro tends to produce greater weight loss than single-pathway GLP-1 medicines. [2][6]

Most of Mounjaro's side effects are a direct result of slowing gastric emptying. When food stays in the stomach longer, it keeps you full but can also cause nausea, bloating, and constipation. Understanding this mechanism helps explain both why the medicine works and why the early weeks of treatment can be uncomfortable for some people.

These side effects are generally mild to moderate and tend to improve after the first four to eight weeks. They also tend to return briefly after each dose increase, then settle again. [1][2]

• Nausea and vomiting: Nausea affects up to 18% of patients and vomiting up to 9%. [1] Both are most common when starting treatment or increasing the dose. Eat smaller, lower-fat meals. Stay upright after eating. Avoid lying down for at least two hours after a meal. Ginger or peppermint may also help. If nausea stops you from eating or drinking normally, contact your doctor before your next dose.
• Diarrhoea: Diarrhoea affects up to 17% of patients. [1] It usually appears early in treatment and is mild to moderate for most people. The main risk is dehydration. Drink plenty of fluids. Eat small, bland meals. Avoid spicy or fatty foods. Do not take products containing sweeteners ending in "ol," such as sorbitol or mannitol, as these can worsen diarrhoea.
• Reduced appetite: Up to 11% of patients report a lower appetite. [1] Mounjaro slows digestion and keeps you feeling full for longer, which naturally reduces how much you want to eat. This can be a welcome effect, but eating too little can leave you without enough nutrients and protein. Try smaller, nutrient-dense meals spread through the day rather than skipping eating altogether.
• Constipation: Constipation affects up to 7% of patients. [1] It can develop at any stage of treatment, not only at the start. Increase your dietary fibre intake gradually, drink more water, and stay physically active. Ask your doctor or pharmacist before using laxatives.
• Indigestion and bloating: Up to 8% of patients experience indigestion. [1] A stomach that empties more slowly feels overfull or causes acid discomfort. Eat smaller, more frequent meals. Do not lie down straight after eating. Limit caffeine and alcohol. Chew food slowly and thoroughly.
• Stomach pain: Stomach pain affects up to 6% of patients. [1] Mild cramping is common, especially in the first months, and usually improves with time. Severe or persistent pain that spreads to your back is different. It can be a sign of pancreatitis, which is a serious condition. Do not manage that kind of pain at home. Contact your doctor promptly.
• Sulphur burps: Many patients report burping with an egg-like smell. [2] This happens because food stays in the stomach longer and produces sulphur-containing gas as it digests. Reduce high-sulphur foods such as eggs, garlic, onions, and cruciferous vegetables. Eating smaller portions and staying well hydrated also helps.
• Injection site reactions: Pain, redness, bruising, and bleeding at the injection site are among the most commonly reported real-world side effects. [5] A 2025 analysis of FDA adverse event reports found injection site pain was the second most frequently reported problem after dosing errors. Rotate the injection site between the abdomen, thigh, and upper arm each week.
• Fatigue: Some patients feel more tired than usual, particularly in the early weeks. [1] This is partly because eating less means less energy for the body. Maintain regular meals with adequate protein even when your appetite is low.
• Dosing errors: Incorrect dose administration was the single most reported problem in a 2025 analysis of 65,974 real-world reports, rising from 1,248 cases in 2022 to 9,800 in 2024. [5] The most common mistakes are missing an injection day, double-dosing, or using the wrong strength pen. Keep a written record of your injection day. Always check you are using the correct pen strength for your current dose before injecting.

These side effects are less common but need prompt medical attention. Contact your doctor immediately or seek emergency care if you develop any of the following. [1][2]

Pancreatitis

Pancreatitis is inflammation of the pancreas. It occurs in less than 1% of patients taking Mounjaro. [1]

Symptoms may include:

• Severe, persistent pain in the upper stomach
• Pain that spreads to the back
• Nausea and vomiting alongside the pain
• Fever

Gallbladder Disease

Gallbladder disease, including gallstones and gallbladder inflammation, occurs in less than 1% of patients taking Mounjaro in clinical trials. [1]

Symptoms may include:

• Sudden pain in the upper right abdomen, often after a fatty meal
• Clay-coloured stools
• Fever
• Yellowing of the skin or the whites of the eyes (jaundice)

Kidney Problems

Mounjaro does not directly damage the kidneys. However, significant vomiting or diarrhoea can cause dehydration, and dehydration can lead to acute kidney injury, which is sudden loss of kidney function. [1][2]

Symptoms to watch for:

• Reduced urine output or very dark urine

• Swelling in the legs or feet

• Unusual tiredness or confusion

Hypoglycaemia (Low Blood Sugar)

Mounjaro does not cause low blood sugar when taken on its own. No cases of hypoglycaemia occurred in patients taking Mounjaro alone during clinical trials. [1] The risk increases when Mounjaro is combined with insulin, affecting 14 to 19% of patients, or with a sulphonylurea, affecting 10 to 14% of patients. [1][3]

Symptoms to watch for:

• Shakiness and sweating

• Rapid heartbeat
• Dizziness or confusion
• Blurred vision

Vision Changes

Some patients with type 2 diabetes experience worsening of diabetic retinopathy, which is damage to the blood vessels at the back of the eye, when blood sugar improves rapidly. [1][2] This is thought to occur because the blood vessels in the retina react to the sudden change in blood sugar levels.

Symptoms may include:

• Blurred vision
• Sudden vision changes
• Floaters (dark spots or threads drifting across your field of vision)
• Vision loss in one or both eyes

Allergic Reactions

Serious allergic reactions to Mounjaro affect approximately 3% of patients, which is higher than the rate reported for Ozempic. [1] Stop Mounjaro immediately and call emergency services if you develop any of the following:

• Hives or rash
• Swelling of the face, lips, tongue, or throat
• Difficulty breathing or swallowing
• Severe dizziness

Heart Rate Increase

Some patients taking Mounjaro experience a mild increase in resting heart rate of approximately 2 to 4 beats per minute. [1] This is generally not clinically significant for most patients but should be monitored in those with pre-existing cardiac conditions.

Mounjaro carries an FDA boxed warning, which is the most serious level of safety warning for prescription medicines. The warning relates to a possible risk of thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), a type of thyroid cancer. Animal studies of tirzepatide showed an increased risk of these tumours in rodents. Whether this risk occurs in people taking Mounjaro at clinical doses is not yet known. [1][2]

Symptoms may include:

• A lump or swelling in the neck
• Hoarseness that does not go away
• Difficulty swallowing
• Shortness of breath

What to do: Do not use Mounjaro if you or a close family member has a personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a genetic condition affecting the endocrine glands. [1][2] Report any of the symptoms above to your doctor promptly during treatment.

Mounjaro (tirzepatide) can sometimes lead to side effects that persist over time. Though uncommon in clinical studies, issues such as digestive disturbances, kidney complications, gallbladder problems, or pancreatitis may occur and could require ongoing medical care.

The duration of side effects varies. Some, like mild nausea or diarrhea, are usually short-lived and may fade within days or weeks as your body adjusts to the medication. Others, particularly more serious reactions, might last longer and demand continuous treatment.

To help reduce the likelihood of side effects, doctors typically begin with the lowest dose and gradually increase it. This stepwise approach allows the body to adapt more smoothly.

If you notice side effects that feel severe, don’t go away, or interfere with daily life, it’s important to reach out to your doctor. They can help determine whether what you’re experiencing is temporary or something that needs long-term management.

Mounjaro is not suitable for everyone. It should be avoided in the following situations: [1][2][4]

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
• History of pancreatitis
• Pregnancy or planned pregnancy
• Breastfeeding (safety data in humans are insufficient)
• Severe gastroparesis or other significant gut motility disorders
• Known hypersensitivity to tirzepatide or any component of the formulation

• Severe or persistent abdominal pain, especially radiating to the back
• Repeated vomiting for more than 24 to 48 hours
• Signs of dehydration: dark urine, dizziness, reduced urination
• Any new or sudden changes in vision
• A lump in the neck, hoarseness, or difficulty swallowing
• Signs of an allergic reaction: hives, swelling, breathing difficulty
• Blood sugar repeatedly falling below 70 mg/dL

For most people, the main challenge with Mounjaro is managing digestive side effects in the first two months of treatment. Starting at the lowest dose and increasing slowly is the most effective strategy for getting through this phase comfortably. Serious side effects are uncommon but real, and knowing what to watch for is an important part of taking this medicine safely.

One practical issue that real-world data highlights is the risk of dosing errors. The mandatory escalation schedule and weekly injection timing mean it is easy to miss a dose, double up, or use the wrong strength pen. Clear records and good communication with your prescribing doctor help avoid these problems. [5]

If you have concerns about any side effects while taking Mounjaro, your doctor is the right first call. Do not stop the medicine without medical guidance. If you have been prescribed Mounjaro and are looking for a reliable source in India, PlatinumRx offers a genuine supply with doorstep delivery (a valid prescription is required).

1. Hannemann K. Mounjaro Side Effects: Common, Severe, Long Term. Drugs.com. Updated March 2025. https://www.drugs.com/sfx/mounjaro-side-effects.html
2. Brewer A, Cox A. Side effects of Mounjaro and how to manage them. Medical News Today. Updated March 2026. https://www.medicalnewstoday.com/articles/drugs-mounjaro-side-effects
3. Diabetes UK. What is Mounjaro? Uses, How it Works and Side Effects. Updated June 2025. https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/mounjaro
4. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. Updated November 2024. https://pi.lilly.com/us/mounjaro-uspi.pdf
5. Almansour HA, Thaibah HA, Alfarhan M, et al. Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025). Healthcare (Basel). 2025;13(18):2259. https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
7. NHS England. Weight Management Injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/
8. European Medicines Agency. Mounjaro: EPAR Summary. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro